FIG 2.

Scattergram comparing 3,598 Enterococcus spp. surveillance isolates (obtained from 2011 to 2013) tested against oritavancin and vancomycin. Breakpoint concentrations for vancomycin (solid vertical lines) were compared to the oritavancin breakpoint (≤0.12 μg/ml for vancomycin-susceptible E. faecalis; broken horizontal line) assigned by the FDA and/or proposed elsewhere based on ECOFF and PK/PD analyses (8, 15–17, 19, 27). A total of 12 and 746 isolates had intermediate susceptibility or resistance to vancomycin, and of those isolates, 93.3% were inhibited by 0.12 μg/ml oritavancin, e.g., they were oritavancin susceptible.